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Serological evidence of cross infection in a dialysis unit
hepatitis-B epidemic. This study provides serological as well as
epidemiological evidence that a dialysis unit hepatitis-B epi-
demic was spread by cross contamination. There were 74
patients and staff who developed HB-Ag-positive hepatitis
during a 28-month hospital surveillance period. Twenty-six of
these cases were intimately related to the dialysis unit (21
dialysis/transplant patients and five hospital staff) and 58 were
not. Representative sera from each group of cases were further
tested for HB-Ag subtype specificity. Thirteen of 14 dialysis/
transplant patients had subtype ay whereas ten of 15 general
hospital patients had the alternate phenotype ad. All four staff
who had probably acquired their infection from dialysis/trans-
plant patients were ay subtype. Eight of the dialysis/transplant
patients had never received blood. Transfusion rate in the
infected dialysis patients was one-third that of leukemic patients
but the hepatitis rate was higher.
Preuve sérologique d'une contamination croisée dans une
unite de dialyse par le virus B de l'hépatite. Ce travail apporte les
preuves sérologiques et épidémiologiques de la contamination
croisée d'une unite d'hémodialyse par Ic virus B de l'hépatite.
Soixante-quatorze malades et membres de l'equipe ont développé
une hépatite HB-Ag positive dans les 28 mois de Ia surveillance
de l'hOpital. Vingt-six de ces cas ont été lies étroitement a Ia
dialyse (21 malades de dialyse ou transplantation et 5 membres
de l'equipe) et 58 ne l'étaient pas. Dans chaque groupe de cas le
serum a été étudié pour identifier les phenotypes de HB-Ag.
Treize des 14 malades de dialyse ou transplantation avaient le
phenotype ay alors que 10 parmi 15 des malades de l'hôpital
general avaient l'autre phenotype ad. Les quatre membres de
l'equipe qui avaient probablement contracté leur infection a
partir de malades de transplantation ou de dialyse avaient le
phenotype ay. Huit des malades de dialyse ou de transplantation
n'avaient jamais recu de sang. Le debit transfusions chez les
malades en dialyse atteints par l'hépatite était le tiers de celui
des malades leucémiques mais l'incidence de l'hépatite a été
plus grande chez les premiers.
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Hepatitis epidemics associated with hepatitis-B
antigen (HB-Ag) cause morbidity and death among
staff as well as patients [1]. Yet the mode of trans-
mission has not been well defined. In spite of circum-
stantial evidence of cross infection [1—3], some
investigators have assumed contaminated transfused
blood to be the main source of individual infection
[4]. Recent recognition of serologically identifiable
hepatitis-B subtypes provides an opportunity to define
the mode of spread with greater certainty [5]. The
following report describes an extensive outbreak of
hepatitis-B in a hemodialysis unit and provides
serological as well as epidemiological evidence that
the epidemic was caused by lateral transmission rather
than by a series of contaminated transfusions.
Methods
Epidemiology. As a result of the occurrence of a
case of hepatitis in a hemodialysis staff member at the
Durham Veterans Administration (VA) Hospital in
early 1971, we began hospital-wide surveillance for
possible new cases. Records of clinical hepatitis from
previous years were also available. Each patient or
staff member with clinical evidence of hepatitis under-
went pertinent history and physical examination with
special attention to the question of intimacy of con-
tact with blood from patients with known circulating
hepatitis-B antigen or known dialysis patients. All
dialysis, transplant and dialysis/transplant staff under-
went monthly blood testing for HB-Ag. From May
1971 to May 1973 all sera were tested for HB-Ag using
counter-electrophoresis (CEP). The diagnosis of
HB-Ag-positive hepatitis was made only if the antigen
was found in the blood by CEP. The period under
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consideration ended in January, 1973, and HB-Ag test
results were monitored until May, 1973. However,
since January, 1973, testing has been done by radio-
immunoassay (RIA) as well. All dialysis patients and
staff found to have HB-Ag by CEP were also positive
by RIA. Moreover, no CEP-negative person in this
group was found to be positive by RIA. Patients and
staff are grouped for the purpose of comparison as
follows: Patients are subdivided according to whether
or not they were dialysis (or renal transplant) patients.
Hospital staff are grouped according to their principal
area of responsibility which is either dialysis-staff or
nondialysis-staff. For the purpose of comparing rates
of acquisition of the HB-Ag antigen in another
frequently transfused group, we monitored trans-
fusion rate and HB-Ag acquisition in a group of 18
consecutive leukemic patients who survived four
months or more while receiving blood products. The
transfusion rate in the HB-Ag-positive dialysis
patients and in a randomly selected group of 21
Hb-Ag-negative patients was calculated for the 24-
month observation period. All blood transfusions
were provided by the Red Cross blood bank and were
screened for the HB-Ag by CEP until January, 1973,
and by RIA thereafter.
Sera from 35 persons with HB-Ag-positive hepatitis
(29 patients and six staff) were tested for subtypes a, y
and d, and results tabulated according to the likely
source of acquisition. Only two of the six staff mem-
bers were employed by the dialysis unit; both had re-
ported a puncture injury with contaminated needles.
Two other staff members (a cardiologist and a trans-
plant surgeon) had been similarly injured by a con-
taminated needle or scapel while working intimately
with known HB-Ag-positive dialysis patients. They are
grouped with the first two as "dialysis related" staff
members for the purpose of subtype distribution
analysis.
Dialysis procedure. During the 28-month-period
under consideration, dialysis was usually performed
in a large open ward with a central dialysate delivery
system, but occasionally with a single patient in a
closely joined single room. An average of slightly over
six patients per day were treated using Travenol1 RSP
equipment with disposable twin coils and tubing.
Patients were and are dialyzed two or three times
every week. We did not attempt reuse of coils. No
attempt was made to isolate permanent equipment
(cannisters, mercury switches or aeronoid baro-
meters). However, as the epidemic became apparent,
clean-up procedures were introduced which included
1 Use of trade names is for identification only and does not
constitute endorsement by the Public Health Service or by the
U.S. Department of Health, Education and Welfare.
formalin rinsing of the cannister and hypochlorite
washing of the nozzles of the mercury switches and
barometers. We also initiated the routine use of
Millipore filters between the nozzles of these devices
and the disposable blood tubing. During the last
eight months, we performed dialysis in a separate area
using single unit home dialysis Travenol equipment,
but procedures otherwise remained the same.
Subtyping. Subtyping of hepatitis-B antigens from
35 patients was performed by an immunodiffusion
method. Glass slides (3 x 2 inches) were covered with
6 ml of 0.5% agarose in 0.1M NaCI containing
0.05M Tris buffer (pH 8). A conventional seven-well
pattern was cut in the agarose layer. Wells were 3 mm
in diameter and 5 mm center to center. A known
guinea pig ad antibody (Research Resources Branch,
National Institute of Allergy and Infectious Diseases,
No. V 801-501-058) was used in conjunction with
known ad and ay antigens purchased from the
American National Red Cross, Blood Research
Laboratory, Bethesda, Maryland. By alternating the
antigen to be typed with known antigens around the
guinea pig antibody in the wells of a single pattern,
the subtype could be determined by observation of the
reactions of partial identity which occurred. Antigens
too weak to be typed by this method were further
examined by a modification of a CEP procedure
described by others [6].
Results
There were 74 cases of HB-Ag positive hepatitis
recognized in our hospital surveillance between
January, 1971 and May, 1973. Forty-six cases occurred
in general hospital patients, many of whom were
known users of parenterally administered illicit drugs,
21 in dialysis/transplant patients and 17 among the
hospital staff. Three of the involved staff members
worked on the dialysis unit. An additional two had
known puncture wounds with sharp objects that had
been contaminated by dialysis patient blood and only
one of these staff hepatitis cases had no known con-
tact with the dialysis/transplant unit or its patients.
During this surveillance period, 94 regular dialysis
patients were exposed on the unit for periods varying
from one month to 27 months. Although data are
incomplete, this period appears to represent an
epidemic. The apparent yearly attack rate (cases! 100
hospital discharges/yr) was 0.04 in 1968, 0.01 in 1969,
0.03 in 1970, 0.4 in 1971 and 0.6 in 1972.
Selected clinical events of the 21 HB-Ag-positive
dialysis patients (l4% of all entrants) are portrayed in
Fig. 1. Only one dialysis/transplant patient (No. 8) had
symptoms suggestive of acute viral hepatitis. His
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Fig. 1. Clinical course and serologic findings in 21 dialysis/trans-
plant patients with known hepatitis-B. TX= transplant surgery at
our center, D=died, A=alive,
bilirubin concentration remained normal (0.4 mg/
100 ml) but serum glutamic oxaloacetic transaminase
(SGOT) activity rose to 192 U and the liver biopsy
specimen showed mild inflammatory changes. Another
dialysis/transplant patient (No. 19) developed severe
liver dysfunction during his terminal two weeks when
he had overwhelming sepsis with Candida albicans.
Nine other patients had elevated SGOT activity (57 to
209 U) and two had slight elevations of bilirubin
concentration (1.4 to 1.6 mg/l00 ml) when the HB-Ag
was first detected. None of these patients had clinical
illness. The one patient with ad subtype had no
clinical or biochemical changes. Autopsy examination
of nine MB-Ag-positive patients revealed microscopic
hepatic inflammation in only two. All dialysis/trans-
plant patients have remained positive. In contrast, all
staff members who have acquired MB-Ag developed
frank clinical hepatitis with jaundice, SGOT over
1000 U, nausea, pain and in four cases arthralgias.
All but one of these individuals has reverted to a
negative reaction for MB-Ag by the RIA method. All
but one (patient No. 1) was dialyzed in our unit prior
to documentation of MB-Ag in the serum. Nine of
these patients were found to be positive when routine
testing was initiated. Among the 12 who were known
to acquire MB-Ag while on maintenance dialysis in
our unit (a negative finding followed by a positive), an
average of eight months elapsed between starting the
program and the first positive test. Some patients had
also been dialyzed elsewhere (usually the Duke
University Unit where surveillance has not revealed a
Table 1. Hepatitis-associated antigen subtype
Subtype Dialysis/ DVAH General
transplant staff a hospital
patients N= 6 patients
N=14 N=15
ay 13 4b 5
ad 1 20 10
a DVAH, Durham Veterans Administration Hospital.
All had been intimately related to the care of dialysis/
transplant patients.
Both were recognized carriers of HB-Ag who had no
known contact with dialysis/transplant patients.
similar epidemic). Twelve of these 21 dialysis patients
have received renal homografts, nine before demon-
stration of the MB-Ag in their blood. Eight of these
patients had never received a blood transfusion, nor
were in known contact with hepatitis nor used illicit
drugs.
The influence of fresh blood transfusions on
acquisition of MB-Ag-positive sera was examined by
comparing the number of transfusions given during
the period of the epidemic in two groups of patients.
No frozen blood was used. MB-Ag-positive hemo-
dialysis patients had one-third as many fresh blood
transfusions as a group of 18 leukemic patients
(9.4 vs. 26.9/patient/yr). Records of a randomly selected
group of MB-Ag-negative hemodialysis patients re-
vealed that the blood transfusion rate was virtually
the same as that of the other dialysis patients (9/
patient/yr). There was, as expected, a large difference
in the type of fresh blood product used. The leukemia
patients generally received platelet concentrates
(20.7/patient/yr) and the dialysis patients primarily
received packed (not washed) red blood cells
(7.8/patient/yr). Only two of these 18 leukemic patients
developed MB-Ag positive sera, whereas the acquisition
rate was 21 of 94 exposed dialysis patients.
MB-Ag subtyping (Table 1) showed a predominance
of subtype ad among general hospital patients, many
of whom were known illicit drug users. In marked
contrast, all but one of the dialysis/transplant patients
with MB-Ag-positive hepatitis were of the ay subtype.
The exception was patient No. 1, a man who may have
been infected at the time he came to our unit. Of the
six staff members tested, four had known exposure to
the dialysis unit patients and also were of the ay sub-
type. The other two staff members with ad subtype
were asymptomatic carriers of the MB-Ag.
Discussion
Although dialysis unit related hepatitis-B out-
breaks are widely reported [1—3], most data demon-
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strating cross contamination have been epidemio-
logical and perhaps not universally accepted. Hence,
reduction of the hepatitis acquisition rate in a dialysis
unit has been alleged to be due to use of frozen blood
[4].
However, in this and a similar report [7], serological
subtyping revealed that all the dialysis unit-acquired
hepatitis was of a single subtype, whereas approxi-
mately two-thirds of the HB-Ag-positive hepatitis
cases in our hospital who were not associated with the
dialysis unit were infected with the other subtype.
While this and the previous report of a subtype-
specific dialysis hepatitis epidemic occurred with
subtype ay, there is little reason to suppose that there
is a special predilection of this group for hemodialysis/
transplant patients because ad infection has also been
reported in similar patients [5]. More likely, the
majority of patients were infected by a contaminated
environment. A recent survey of dialysis unit hepatitis
outbreaks by the United States Center for Disease
Control provided substantial epidemiological data
that cross contamination was common [8].
Infected blood used for transfusion may have been
the source of the original introduction of the virus to
the unit but does not appear to have been responsible
for the high rate of new case appearance. In this study,
leukemia patients received nearly three times as much
blood product (usually platelets) as dialysis patients
but had no higher rate of acquisition of HB-Ag.
Moreover, several dialysis patients who developed
hepatitis had not received blood. The reported ad:ay
ratio of 5.8: 1, 7.3: 1 and 10.3: 1 at nationwide, south-
east and local Red Cross blood collection centers,
respectively, reflects a preponderance of subtype ad in
contrast to our findings [9].
The source of the environmental contamination is
uncertain and may well be complex. Our personnel
have always used gloves in handling equipment and
patients, and usually changed them in going from
patient to patient. Blood is commonly spilled on linen
and equipment. No attempt was made to isolate coil
cannisters but they were routinely rinsed; moreover,
the possibility that virus would cross from cannister to
internal coil seems remote even if the coil ruptures.
This is due to the high pressure gradient from inside to
outside and the practice of stopping dialysis at the
first detection (Ames Hemastix) of minor blood leaks.
A more likely source of contamination is the sharing
of monitoring devices whose connecting elements fit
inside the disposable blood tubing side-arms. Because
of that possibility, we have recently employed many
recommendations of the Rosenheim Committee [10]
and others [1]. Preventative measures undertaken
include monthly testing of all patients and staff,
identification by name of mercury switches and
aeronoid barometers to prevent cross usage, the
employment of Millipore filter protective devices
between the connectors and tubing and daily washing
of connectors with hypochiorite solution. We have
maintained our policy of monthly surveillance of
patients, labeling of charts and materials of known
carriers, limited use of blood, screening of blood units
at the blood bank and transfer of most patients to
home dialysis. Our epidemic rate appears to have
fallen as determined by findings of the RIA test
which has been used since the outbreak for sur-
veillance of the patients and staff. For eight months
we discovered no further acquisition of HB-Ag in
spite of the admission of 22 new susceptible dialysis
patients to the maintenance program. However, three
patients have recently converted to HB-Ag-positive
during the following four months (16 new admissions).
All three of these were also of the subtype ay. This
experience certainly suggests that control of this in-
fection is difficult in a complex medical environment.
We have continued the policy outlined herein and
have redoubled our efforts to disinfect blood-con-
taminated linen, equipment and floors.
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